Gilead Sciences, Inc

Introduction
Gilead Sciences, Inc. is a leading American biopharmaceutical company founded in 1987, specializing in antiviral drugs and breakthrough treatments for infectious diseases. The company is best known for its therapies in HIV/AIDS, hepatitis B and C, influenza, and COVID-19, as well as its growing focus on oncology and inflammatory diseases. With its groundbreaking research and innovative medicines, Gilead has transformed the lives of millions of patients worldwide.

Mission and Vision

Mission: To discover, develop, and deliver innovative therapeutics in areas of unmet medical need that improve patient care.
Vision: To create a healthier world by advancing groundbreaking medicines for life-threatening diseases.

Products and Services

HIV/AIDS: Biktarvy, Truvada, Descovy, and Genvoya – leading treatments and PrEP (pre-exposure prophylaxis) options.
Hepatitis: Harvoni, Sovaldi, and Epclusa, which revolutionized hepatitis C treatment with high cure rates.
COVID-19: Veklury (Remdesivir), the first FDA-approved treatment for COVID-19.
Oncology: Yescarta and Tecartus (CAR-T therapies for blood cancers).
Inflammation & Respiratory: Therapies in development for inflammatory diseases and viral infections.

Growth and Innovation
Gilead has built its reputation on antiviral innovation, especially with HIV and hepatitis C therapies that redefined treatment standards. More recently, the company has expanded into oncology through acquisitions such as Kite Pharma (CAR-T therapies) and Immunomedics, adding the breast cancer drug Trodelvy to its portfolio. Gilead continues to invest in gene therapy, cell therapy, and long-acting antivirals, alongside partnerships with global health organizations.

Global Impact
Gilead’s medicines are used in more than 35 million patients worldwide. The company has played a crucial role in global HIV/AIDS programs, improving access to antiretroviral therapies in low- and middle-income countries. During the COVID-19 pandemic, Gilead’s Remdesivir was a frontline treatment globally. Beyond innovation, Gilead is deeply committed to health equity, access to medicines, and sustainability initiatives.